TapewireFind a company

person · Reporting owner

Schambye Hans T.

Disclosed activity across 1 company

Tapewire entity
69926
SEC CIK
0001825776

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Damora Therapeutics, Inc.GLTO · Entity 4602Director · Chief Executive OfficerJanuary 02, 2026January 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Damora Therapeutics, Inc.

Report date January 02, 2026 · Filed January 06, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect4,682 Ending reported balance After 2026-01-02 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-01-02 · Exercise / conversion · Acquired 1,360 · Balance 5,382

F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.

Row 2 · 2026-01-02 · Sale · Disposed 700 · Balance 4,682

F2: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect2,640 Reported balance After 2026-01-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-01-02 · Exercise / conversion · Disposed 1,360 · Balance 2,640

F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.

F3: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.

F2: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person.

F3: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 02, 2026 Filed Jan 6, 2026 21:30 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 Exercise / conversionRestricted Stock Units · Derivative 1,360 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-004573 · ownership.xml · derivative · entry 3

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,640

Underlying: Common Stock · 1,360 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.

F3 · derivative.exercise_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.

F3 · derivative.expiration_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.

Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:30 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 SaleCommon Stock 700 $21.38 $14,966.00
Disclosure

SEC source: 0001193125-26-004573 · ownership.xml · nonDerivative · entry 2

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,682

F2 · kind: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person.

Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:30 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 Exercise / conversionCommon Stock 1,360 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-004573 · ownership.xml · nonDerivative · entry 1

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,382

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.

Read SEC document
July 03, 2025 Filed Jul 8, 2025 20:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 Exercise / conversionRestricted Stock Units · Derivative 1,360 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-094576 · ownership.xml · derivative · entry 3

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock · 1,360 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.

F3 · derivative.exercise_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.

F3 · derivative.expiration_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.

Read SEC document
July 03, 2025 Filed Jul 8, 2025 20:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 SaleCommon Stock 735 $3.38 $2,484.30
Disclosure

SEC source: 0000950170-25-094576 · ownership.xml · nonDerivative · entry 2

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,022

F2 · kind: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person.

Read SEC document
July 03, 2025 Filed Jul 8, 2025 20:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 Exercise / conversionCommon Stock 1,360 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-094576 · ownership.xml · nonDerivative · entry 1

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,757

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.

Read SEC document
January 03, 2025 Filed Jan 7, 2025 21:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 GrantStock Option (right to buy) · Derivative 16,400 $0.00 Strike: $5.70 $0.00
Disclosure

SEC source: 0000950170-25-002811 · ownership.xml · derivative · entry 4

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,400

Underlying: Common Stock · 16,400 shares

Expires 2035-01-03

F4 · derivative.exercise_date: 25% of the shares subject to such option will vest and become exercisable on January 3, 2026 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
January 03, 2025 Filed Jan 7, 2025 21:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 Exercise / conversionRestricted Stock Units · Derivative 2,640 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-002811 · ownership.xml · derivative · entry 3

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,360

Underlying: Common Stock · 2,640 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.

F3 · derivative.exercise_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.

F3 · derivative.expiration_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.

Read SEC document
January 03, 2025 Filed Jan 7, 2025 21:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 SaleCommon Stock 1,341 $5.60 $7,509.60
Disclosure

SEC source: 0000950170-25-002811 · ownership.xml · nonDerivative · entry 2

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,397

F2 · kind: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person.

Read SEC document
January 03, 2025 Filed Jan 7, 2025 21:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 Exercise / conversionCommon Stock 2,640 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-002811 · ownership.xml · nonDerivative · entry 1

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,738

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.

Read SEC document
October 09, 2024 Filed Oct 11, 2024 21:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 GrantStock Option (right to buy) · Derivative 44,100 $0.00 Strike: $7.49 $0.00
Disclosure

SEC source: 0000950170-24-114384 · ownership.xml · derivative · entry 1

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,100

Underlying: Common Stock · 44,100 shares

Expires 2034-10-09

F1 · derivative.exercise_date: The shares subject to such option vest in 48 equal monthly installments over four years from the Award Date, subject in each case to the grantee's continued service through the applicable vesting date.

Read SEC document
January 03, 2024 Filed Jan 5, 2024 21:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 GrantRestricted Stock Units · Derivative 200,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000950170-24-002433 · ownership.xml · derivative · entry 1

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires not disclosed

F1 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of Galecto, Inc. One-third of the restricted stock units subject to the award will vest on January 3, 2025 and the remaining restricted stock units will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.

F1 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of Galecto, Inc. One-third of the restricted stock units subject to the award will vest on January 3, 2025 and the remaining restricted stock units will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.

Read SEC document
January 04, 2023 Filed Jan 5, 2023 21:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 GrantStock Option (right to buy) · Derivative 300,000 $0.00 Strike: $1.21 $0.00
Disclosure

SEC source: 0001209191-23-001760 · doc4.xml · derivative · entry 1

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2033-01-03

F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
March 22, 2022 Filed Mar 23, 2022 12:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 PurchaseCommon Stock 5,000 $2.15 $10,750.00
Disclosure

SEC source: 0001209191-22-020682 · doc4.xml · nonDerivative · entry 1

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,428

Read SEC document
January 04, 2022 Filed Jan 6, 2022 22:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 GrantStock Option (right to buy) · Derivative 287,500 $0.00 Strike: $3.24 $0.00
Disclosure

SEC source: 0001209191-22-002215 · doc4.xml · derivative · entry 1

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 287,500

Underlying: Common Stock · 287,500 shares

Expires 2032-01-03

F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
November 09, 2021 Filed Nov 10, 2021 13:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 PurchaseCommon Stock 4,500 $3.50 $15,750.00
Disclosure

SEC source: 0001209191-21-063798 · doc4.xml · nonDerivative · entry 1

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,428

Read SEC document
June 24, 2021 Filed Jun 24, 2021 20:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 PurchaseCommon Stock 3,000 $5.11 $15,330.00
Disclosure

SEC source: 0001209191-21-042986 · doc4.xml · nonDerivative · entry 1

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,928

Read SEC document
January 05, 2021 Filed Jan 7, 2021 21:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 GrantStock Option (right to buy) · Derivative 230,000 $0.00 Strike: $13.00 $0.00
Disclosure

SEC source: 0001209191-21-002476 · doc4.xml · derivative · entry 1

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,000

Underlying: Common Stock · 230,000 shares

Expires 2031-01-05

F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 5, 2022 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
November 02, 2020 Filed Nov 5, 2020 01:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 ConversionSeries C-1 Preferred Stock · Derivative 5,359 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-030412 · doc4.xml · derivative · entry 4

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,931 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date.

F1 · derivative.exercise_date: The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date.

F1 · derivative.expiration_date: The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date.

Read SEC document
November 02, 2020 Filed Nov 5, 2020 01:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 ConversionCommon Stock 13,931 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-030412 · doc4.xml · nonDerivative · entry 1

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,928

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date.

Read SEC document
October 07, 2020 Filed Nov 5, 2020 01:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 GrantStock Option (right to buy) · Derivative 519,940 $0.00 Strike: $7.70 $0.00
Disclosure

SEC source: 0000899243-20-030412 · doc4.xml · derivative · entry 3

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 519,940

Underlying: Common Stock · 519,940 shares

Expires 2030-10-06

F2 · derivative.exercise_price: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.

F5 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F2 · shares: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.

F4 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on September 27, 2021 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

F2 · derivative.underlying_shares: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.

F2 · balance_after: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.

Read SEC document
June 24, 2020 Filed Nov 5, 2020 01:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 GrantStock Option (right to buy) · Derivative 207,976 $0.00 Strike: $1.95 $0.00
Disclosure

SEC source: 0000899243-20-030412 · doc4.xml · derivative · entry 2

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,976

Underlying: Common Stock · 207,976 shares

Expires 2030-06-24

F2 · derivative.exercise_price: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.

F5 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F2 · shares: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.

F3 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on October 22, 2019 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

F2 · derivative.underlying_shares: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.

F2 · balance_after: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.